Insight Molecular Diagnostics (IMDX) Amortization of Deferred Charges (2017 - 2022)

Insight Molecular Diagnostics has reported Amortization of Deferred Charges for 6 years, with the latest figure at $1000.0 in Q3 2022.

• Quarterly Amortization of Deferred Charges fell 92.31% year-over-year to $1000.0 in Q3 2022, while the trailing twelve-month figure through Dec 2022 was $12000.0 (down 78.57% YoY) and the FY2022 annual result came in at $12000.0, down 78.57% from the prior year.
• Amortization of Deferred Charges slipped to $1000.0 in Q3 2022 per IMDX's latest filing, from $4000.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $35000.0 in Q1 2020 and troughed at $1000.0 in Q3 2022.
• A 5-year average of $16105.3 and a median of $15000.0 in 2018 frame the typical range for Amortization of Deferred Charges.
• The sharpest annual moves came in 2018 and 2022: Amortization of Deferred Charges jumped 633.33% in 2018, then slumped 92.31% in 2022.
• Over 5 years, Amortization of Deferred Charges stood at $15000.0 in 2018, then soared by 93.33% to $29000.0 in 2019, then declined by 24.14% to $22000.0 in 2020, then slumped by 54.55% to $10000.0 in 2021, then sank by 90.0% to $1000.0 in 2022.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $1000.0, $4000.0, and $7000.0 for Q3 2022, Q2 2022, and Q1 2022 respectively.